Trastuzumab plus Pertuzumab (combination)(Roche / Genentech)은 Cancer 표적 항체로, Cancer; Tumors 영역에서 개발·상용화 중입니다. 작용기전: of ProAgio, which includes reducing hypoxia and modulating TME. Phase 2에서 효능·안전성 신호를 검증 중입니다. 대표 임상 효능: ORR 88.6% (ClinicalTrials.gov NCT02586025). 차별점: Novel Cell-Free Preservation Solution for Human Cardiomyocyte Protection: A Proof-of-Concept Study.
Cancer
Cancer; Tumors
Recruiting
NK cells by a combinatorial immunotherapy approach simultaneously e
Novel Cell-Free Preservation Solution for Human Cardiomyocyte Protection: A Proof-of-Concept Study
of ProAgio, which includes reducing hypoxia and modulating TME
NK cell antibody-dependent cellular cytotoxicity
apoptosis in human cardiomyocytes under static cold and normothermic storage conditions
biomarkers and sex hormone receptor profiles in assessing post-surgical prognosis among HCC patients
resistance to NK cells by a combinatorial immunotherapy approach simultaneously enabling NK tumor-specific-targeting via chimeric ant
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.
Trastuzumab plus Pertuzumab (combination)(Roche / Genentech)은 Cancer 표적 항체로, Cancer; Tumors 영역에서 개발·상용화 중입니다. 작용기전: of ProAgio, which includes reducing hypoxia and modulating TME. Phase 2에서 효능·안전성 신호를 검증 중입니다. 대표 임상 효능: ORR 88.6% (ClinicalTrials.gov NCT02586025). 차별점: Novel Cell-Free Preservation Solution for Human Cardiomyocyte Protection: A Proof-of-Concept Study.
Cancer
Cancer; Tumors
Recruiting
NK cells by a combinatorial immunotherapy approach simultaneously e
Novel Cell-Free Preservation Solution for Human Cardiomyocyte Protection: A Proof-of-Concept Study
of ProAgio, which includes reducing hypoxia and modulating TME
NK cell antibody-dependent cellular cytotoxicity
apoptosis in human cardiomyocytes under static cold and normothermic storage conditions
biomarkers and sex hormone receptor profiles in assessing post-surgical prognosis among HCC patients
resistance to NK cells by a combinatorial immunotherapy approach simultaneously enabling NK tumor-specific-targeting via chimeric ant
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.